{"id":5010,"date":"2026-01-12T08:34:33","date_gmt":"2026-01-12T08:34:33","guid":{"rendered":"https:\/\/cognitionconferences.com\/clinicalresearch\/?post_type=speaker&#038;p=5010"},"modified":"2026-01-12T08:34:33","modified_gmt":"2026-01-12T08:34:33","slug":"nazaire-bermal-nancy","status":"publish","type":"speaker","link":"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/","title":{"rendered":"Nazaire-Bermal  Nancy"},"content":{"rendered":"<p><strong>Abstract<\/strong><\/p>\n<p>The varicella vaccine (VarV) produced by Sinovac (Dalian) obtained World Health Organization (WHO) prequalification in November 2022. However, no direct comparative studies have been conducted between VarV and other WHO-prequalified varicella vaccines. The study aimed to assess the immunogenicity and safety of Sinovac\u2019s VarV compared with Merck Sharp &amp; Dohme\u2019s (MSD) VARIVAX\u00ae following a single dose administration. This Phase III, randomized, double-blind, active-controlled, non-inferiority trial conducted in the Philippines. Healthy children aged 12 to 15 months were enrolled. Eligible participants were randomly assigned (1:1) to receive a single dose of varicella vaccine either manufactured by Sinovac (Test group) or MSD (Active control group).Immunogenicity was evaluated 6 weeks after vaccination by enzyme-linked immunosorbent assay. The primary immunogenicity endpoint was seroresponse rate in participants who were seronegative at baseline (varicella-zoster virus antibodyconcentration \uff1c 10 mIU\/mL), as well as the secondary endpoint geometric meanconcentration (GMC). Adverse events (AEs) were monitored for 6 weeks after vaccination. Among 484 participants analyzed, seroresponse rates were 98.85% and 98.88% in the Test group and Active control group, respectively, with a difference of -0.03% (95% CI: &#8211; 3.10%, 2.99%). GMCs were 35.73 mIU\/mL and 37.34 mIU\/mL, respectively, with the ratioof 0.96 (95% CI: 0.86, 1.06). Both immunogenicity endpoints reached the prespecified non-inferiority criteria. Furthermore, the incidence of adverse reactions (ARs) in the Test group was lower than that in the Active control group (38.08% vs 55.51%). Conclusions: Sinovac\u2019s VarV demonstrated non-inferior immunogenicity to WHO-prequalified comparator vaccine (VARIVAX\u00ae) and favorable safety profile. These findings indicated that VarV (Sinovac) met WHO standards for varicella vaccine evaluation, supporting its global use consideration.<\/p>\n","protected":false},"featured_media":5007,"template":"","meta":{"_acf_changed":false},"schedule":[5],"speaker-category":[6],"class_list":["post-5010","speaker","type-speaker","status-publish","has-post-thumbnail","hentry","schedule-day-1","speaker-category-speakers"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nazaire-Bermal Nancy - Cognition Conferences<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nazaire-Bermal Nancy - Cognition Conferences\" \/>\n<meta property=\"og:description\" content=\"Abstract The varicella vaccine (VarV) produced by Sinovac (Dalian) obtained World Health Organization (WHO) prequalification in November 2022. However, no direct comparative studies have been conducted between VarV and other WHO-prequalified varicella vaccines. The study aimed to assess the immunogenicity and safety of Sinovac\u2019s VarV compared with Merck Sharp &amp; Dohme\u2019s (MSD) VARIVAX\u00ae following a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/\" \/>\n<meta property=\"og:site_name\" content=\"Cognition Conferences\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-content\/uploads\/2026\/01\/Nazaire-Bermal-Nancy.png\" \/>\n\t<meta property=\"og:image:width\" content=\"216\" \/>\n\t<meta property=\"og:image:height\" content=\"174\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/speaker\\\/nazaire-bermal-nancy\\\/\",\"url\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/speaker\\\/nazaire-bermal-nancy\\\/\",\"name\":\"Nazaire-Bermal Nancy - Cognition Conferences\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/speaker\\\/nazaire-bermal-nancy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/speaker\\\/nazaire-bermal-nancy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Nazaire-Bermal-Nancy.png\",\"datePublished\":\"2026-01-12T08:34:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/speaker\\\/nazaire-bermal-nancy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/speaker\\\/nazaire-bermal-nancy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/speaker\\\/nazaire-bermal-nancy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Nazaire-Bermal-Nancy.png\",\"contentUrl\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Nazaire-Bermal-Nancy.png\",\"width\":216,\"height\":174},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/speaker\\\/nazaire-bermal-nancy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nazaire-Bermal Nancy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/#website\",\"url\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/\",\"name\":\"Cognition Conferences\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cognitionconferences.com\\\/clinicalresearch\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nazaire-Bermal Nancy - Cognition Conferences","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/","og_locale":"en_US","og_type":"article","og_title":"Nazaire-Bermal Nancy - Cognition Conferences","og_description":"Abstract The varicella vaccine (VarV) produced by Sinovac (Dalian) obtained World Health Organization (WHO) prequalification in November 2022. However, no direct comparative studies have been conducted between VarV and other WHO-prequalified varicella vaccines. The study aimed to assess the immunogenicity and safety of Sinovac\u2019s VarV compared with Merck Sharp &amp; Dohme\u2019s (MSD) VARIVAX\u00ae following a [&hellip;]","og_url":"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/","og_site_name":"Cognition Conferences","og_image":[{"width":216,"height":174,"url":"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-content\/uploads\/2026\/01\/Nazaire-Bermal-Nancy.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/","url":"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/","name":"Nazaire-Bermal Nancy - Cognition Conferences","isPartOf":{"@id":"https:\/\/cognitionconferences.com\/clinicalresearch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/#primaryimage"},"image":{"@id":"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/#primaryimage"},"thumbnailUrl":"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-content\/uploads\/2026\/01\/Nazaire-Bermal-Nancy.png","datePublished":"2026-01-12T08:34:33+00:00","breadcrumb":{"@id":"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/#primaryimage","url":"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-content\/uploads\/2026\/01\/Nazaire-Bermal-Nancy.png","contentUrl":"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-content\/uploads\/2026\/01\/Nazaire-Bermal-Nancy.png","width":216,"height":174},{"@type":"BreadcrumbList","@id":"https:\/\/cognitionconferences.com\/clinicalresearch\/speaker\/nazaire-bermal-nancy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cognitionconferences.com\/clinicalresearch\/"},{"@type":"ListItem","position":2,"name":"Nazaire-Bermal Nancy"}]},{"@type":"WebSite","@id":"https:\/\/cognitionconferences.com\/clinicalresearch\/#website","url":"https:\/\/cognitionconferences.com\/clinicalresearch\/","name":"Cognition Conferences","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cognitionconferences.com\/clinicalresearch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-json\/wp\/v2\/speaker\/5010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-json\/wp\/v2\/speaker"}],"about":[{"href":"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-json\/wp\/v2\/types\/speaker"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-json\/wp\/v2\/media\/5007"}],"wp:attachment":[{"href":"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-json\/wp\/v2\/media?parent=5010"}],"wp:term":[{"taxonomy":"schedule","embeddable":true,"href":"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-json\/wp\/v2\/schedule?post=5010"},{"taxonomy":"speaker-category","embeddable":true,"href":"https:\/\/cognitionconferences.com\/clinicalresearch\/wp-json\/wp\/v2\/speaker-category?post=5010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}